NUVB Nuvation Bio Inc - Ordinary Shares - Class A

$NUVB Today's news should increase the probability of large tutes and specialty biotech funds building their positions. With NUVB's new label, showing a 49.6 mos median PFS, institutional models can safely project stable multi-yr recurring cash flows from every frontline patient start. Recognize Ibtrozi now has the advantage not only with the label expansion but with NCCN guideline SOC recommendation. This alone erodes GSK's pipeline advantage with large Hospital systems.

$NUVB yet ANOTHER GREAT conference for Nuvation Bio and Dr. Hung. The science and leadership shows the value of this company. Now let’s be for real here market makers. Cause I know they would have someone watching this board. Enough is enough holding this down for letting funds collect the cheap shares. This should be sitting at 12 or 13 by now. Enough with the manipulation let the F*ckin thing run!!! Been in since FDA approval rode it up and rode it down. It’s F*ckin time!!!! Let’s go!!!!

$NUVB I have been cautiously aggressive on Nuvation over the past 18 months. I will now take the word -cautiously - out of this equation. I am full steam ahead with additional shares at this price. I see no downside to this play. I have too much confidence in how Hung has brought this to market. And now, fast track for a second potential? Just icing on the buy and hold thesis. My opinion only.

$NUVB I saw from a link were it says that GSK drug is better than Ibtozi's drug.. Well GSK doesn't show the whole picture as they know IBTROZI is still much better than their drug.. Jideytro's new 94% first-line ORR is excellent and makes it a serious IBTROZI competitor, but it does not establish that Jideytro is the better drug. The Jideytro dataset has 94 TKI-naïve patients and only ~15 months median follow-up, whereas IBTROZI has 157 TKI-naïve patients, 89.8% ORR, 49.7-month median DOR (Meaning roughly half the responding patients were still responding around four years later !!!) and 46.1-month median PFS while the latest TRUST-I dataset was approximately 49.6 months!!! In addition, ARROS-1 excluded patients with known oncogenic drivers other than ROS1, whereas TRUST-I ( Ibtrozi) placed no restriction on concurrent oncogenic driver mutations including oncogenic drivers, making a simple 94% vs 89.8% ORR comparison inappropriate. More in the comments..

$NUVB Okay great news today 4 months ahead of schedule Now let's go with MHRA approval.

$NUVB NUVB (NP)- At Citigroup Biopharma Summit, Nuvation bio highlighted progress for safusidenib in a number of pivotal trials as well as unprecedented 52% response rate at 3 years with 79% non-progression. They are enrolling multiple studies covering all four types of glioma. Vorasidenib had 41% progression at year 2 vs just 12% for safusidenib. Vorasidenib is on about $2 billion annual run rate after just 18 months on the market. They have treated over 5,500 patients, which means 1/4 of those (over 1,000 patients) are progressing or have already progressed (significant need for safusidenib to fill). They intend to pursue a conversation with the FDA on TGR (tumor growth rate) as another endpoint to consider that could come even sooner than response rate. CEO's hope is whether patients have low-grade or high-grade disease, at some point they'll simply start with safusidenib vs switching from vora because the former is clearly a superior agent. They are comfortable on cash (~$700M).

$NUVB Extra averaging UP WITH 2,000 shares 9/11 and yesterday are paying off. Average still just $4.65.🫡

$NUVB Previously at AACR 2026, the pooled analysis of all TKI-naïve patients in the TRUST-I and TRUST-II studies presented showed a confirmed objective response rate (ORR) of 89.8% and a median duration of response (DOR) of 49.7 months. At WCLC, one of the new analyses presented in the poster revealed consistent response rates regardless of prior chemotherapy exposure. Among TKI-naïve patients: ORR was 90.0% in those with prior chemotherapy (n=30) and 89.8% in those with no prior chemotherapy (n=127). Median DOR was 48.3 months and 54.3 months, respectively.

$NUVB It all comes together as it’s supposed to. Ibtrozi is the SoC. Can Dr Hung partner with a testing company next? Share some profits but take over the market asap.

$NUVB The just released efficacy data on Zidesamtinib say that Zidesamtinib is about as good as Ibtrozi. However, despite the numericals, this data DOES NOT say that Zidesamtinib is better. Let me explain. Two main factors are involved here: 1. The trial ARROS-1 for Zide enrolled patients far more selective than the trials TRUST-1&2 for Ibtrozi; and 2. The number of enrolled patients relevant to the published numbers is 94 in ARROS-1 while TRUST-1&2 combined was 157. Factor 1 says that had Ibtrozi been tested with ARROS-1 patients, Its numerical statistics would likely be similar to Zide's and perhaps even better since the number of patients with prior CNS would reduce. Factor 2 says that there is far more uncertainty in the statistics for Zide than for Ibtrozi. When the statistics are adjusted for these uncertainty, the two drugs will likely have the same profile, esp. in light of the above. Continue in the comment.

$NUVB Approval comes four months ahead of PDUFA date... My kisses to the fuds and shorties..

$NUVB 1. IBTROZI® (taletrectinib) — ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)The company will present new subgroup analyses of pivotal data from its Phase 2 TRUST-I and TRUST-II trials. These findings will detail efficacy and safety across specific patient subgroups at:IASLC 2026 World Conference on Lung Cancer (WCLC): September 12–15, 2026, in Seoul, South Korea.European Society for Medical Oncology (ESMO) Annual Congress: October 23–27, 2026, in Madrid, Spain.Note: The FDA accepted a supplemental New Drug Application (sNDA) with updated data for IBTROZI, carrying a target action date of January 4, 2027.

Citizens reiterated $NUVB Market Outperform-$10 NUVL - $GSK $BMY RHHBY PFE Here's what Citizens said in its note: At the World Conference on Lung Cancer, clinical updates for Nuvalent/GlaxoSmithKline's (NUVL/GSK) ROS1 TKI, zidesamtinib, demonstrated a competitive profile in the TKI-naïve setting, but immaturity of the dataset and the two-year head start for NUVB's IBTROZI – which we still view as best-in-class, represent a large hill to climb for the potential newcomer. We maintain our Market Outperform rating and $10 DCF-derived price target for NUVB as we continue to monitor the launch.

$NUVB I am sorry but like come on. This is absolutely blatant manipulation. This needs to legally be dealt with. I’m sorry enough is enough.

$NUVB This should be a great day after the devastating week we had. Let's hope It jumps Up today 🤑 but even if It doesn't it's just a Matter of time and patience.

$NUVB gemini: This sNDA (supplemental New Drug Application) update has a strong commercial, clinical, and regulatory impact on Nuvation Bio. Commercial Impact & Market Position * Strengthening Market Leadership: By 2026, IBTROZI has grown into the most prescribed ROS1 inhibitor for new patients in the U.S. Officially including a duration of response of over 4 years (49.7 months) for TKI-naïve patients on the drug label provides the solid, approved evidence physicians need to choose IBTROZI as their first-line treatment over competitors like crizotinib or entrectinib. * Higher Revenue & Longer Treatment Duration: Because patients stay on treatment for an average of four years without disease progression, individual patients remain on the drug much longer, generating higher cumulative revenue per patient. Regulatory Compliance & Operational Security

$NUVB Vora has less than 3 years to make money in low grade glioma.. Then comes Safu were it will dominate in both low and high glioma.. patients and doctors will of course prefer it over Vora.. who doesn't want to live longer.. Exciting times to come.. it is still cheap.. when it goes to 10+, more and more funds will start buying.. I don't think Hung will sell for 20B... too little in my opinion.. It depends from the vision that he will have in the future !

$NUVB Nuvation is a pure spec investment. Yeah right- Ha - here’s my view of “pure spec” entertainment! The guy is laughable!

$NUVB today’s stock chart looks like a Six Flags main attraction! Make sure your seat belt and neck brace are properly fastened.

$NUVB I’m praying the market tanks and this dumps under $4. The lower this goes the better entry I get